Thirty patients who had curative surgery for sigmoid and rectal carcinoma were studied by immunoscintigraphy using a new monoclonal antibody: B72.3 radiolabeled with Iodine-131 (I-131) or Indium-111 (In-111). Results were compared with other conventional diagnostic procedures such as computed tomography, ultrasound, endoscopy, and tumor markers. Seven patients had local recurrences and/or distant metastases. Immunoscintigraphy identified all local recurrences (five cases) that were confirmed by CT and was able to localize three of five liver metastases (two false-negatives). Furthermore, immunoscintigraphy also recorded a false-positive. Preliminary use of B72.3 shows good potential for the evaluation and detection of neoplastic sites.
Immunoscintigraphy In the Follow-up of Patients Operated On For Carcinoma of the Sigmoid and Rectum - Preliminary-report With A New Monoclonal-antibody - B72.3 / Renda, Andrea; M., Salvatore; M., Sava; R., Landi; S., Lastoria; L., Coppola; J., Schlom; D., Colcher; G., Zannini. - In: DISEASES OF THE COLON & RECTUM. - ISSN 0012-3706. - STAMPA. - 30:9(1987), pp. 683-686. [10.1007/BF02561688]
Immunoscintigraphy In the Follow-up of Patients Operated On For Carcinoma of the Sigmoid and Rectum - Preliminary-report With A New Monoclonal-antibody - B72.3
RENDA, ANDREA;
1987
Abstract
Thirty patients who had curative surgery for sigmoid and rectal carcinoma were studied by immunoscintigraphy using a new monoclonal antibody: B72.3 radiolabeled with Iodine-131 (I-131) or Indium-111 (In-111). Results were compared with other conventional diagnostic procedures such as computed tomography, ultrasound, endoscopy, and tumor markers. Seven patients had local recurrences and/or distant metastases. Immunoscintigraphy identified all local recurrences (five cases) that were confirmed by CT and was able to localize three of five liver metastases (two false-negatives). Furthermore, immunoscintigraphy also recorded a false-positive. Preliminary use of B72.3 shows good potential for the evaluation and detection of neoplastic sites.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.